<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859495</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB9658</org_study_id>
    <nct_id>NCT00859495</nct_id>
  </id_info>
  <brief_title>Trimodal Lung-Sparing Treatment of Pleural Mesothelioma</brief_title>
  <official_title>Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the feasibility (as determined by lack of&#xD;
      serious adverse events) and tolerability (as determined by patient's ability to complete the&#xD;
      study) of a multimodal lung sparing regimen of surgery, interpleural and intravenous&#xD;
      chemotherapy, and local P-32 irradiation for malignant pleural mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current surgical and/or chemotherapeutic approaches for malignant pleural mesothelioma are&#xD;
      unsatisfactory and have not been shown to significantly prolong survival, and often lead to&#xD;
      worsened pulmonary function and quality of life. We will investigate whether a prospective&#xD;
      trial of trimodal (surgery, pleural chemotherapy, and pleural radiation) therapy can improve&#xD;
      the overall 1 year survival in patients with malignant pleural mesothelioma. The proposed&#xD;
      treatment will include exploratory thoracoscopy, placement of Mediport catheters into the&#xD;
      pleural space, intraoperative chemotherapy, repeated intraperitoneal chemotherapy, and&#xD;
      intrapleural instillation of radioactive P32 to radiate the pleural surfaces. In addition,&#xD;
      because this study is randomized, half the patients will receive an additional three&#xD;
      intravenous systemic chemotherapy treatments of cisplatin and pemetrexed (Alimta) in tandem&#xD;
      with their intrapleural chemotherapy (weeks 3, 6, and 9 only).&#xD;
&#xD;
      The potential significance of this research is that such treatment may render it less&#xD;
      necessary to surgically remove the affected lungs in whole or in part, in order to achieve&#xD;
      significant disease cytoreduction. We hope to alter the currently accepted paradigm that&#xD;
      major lung surgery is an inescapable component of such treatment, and advance the concept&#xD;
      that a combination of judicious preparative surgery, systemic chemotherapy, and locoregional&#xD;
      drug treatment of the pleural surfaces may offer the best hope for prolongation of survival&#xD;
      with intact lung function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Were Able to Complete Trimodal Therapy (Combination of Surgery, Intrapleural and Systemic Chemotherapy and P-32 Radiotherapy).</measure>
    <time_frame>20 weeks</time_frame>
    <description>To determine the feasibility of multimodal lung sparing regimen. Intrapleural chemotherapy (12 weeks) will be administered within two weeks after surgery. Approximately 30 days post last dose of chemotherapy (+/- 14 days), the patient should be reassessed for resolution of any treatment-related toxicity which may have occurred during the course of study participation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Multimodal lung sparing regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrapleural chemotherapy plus systemic chemotherapy:&#xD;
Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.</description>
    <arm_group_label>Multimodal lung sparing regimen</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Platinum-based antineoplastic</description>
    <arm_group_label>Multimodal lung sparing regimen</arm_group_label>
    <other_name>Cisplatinum</other_name>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Folate Analog Metabolic Inhibitor</description>
    <arm_group_label>Multimodal lung sparing regimen</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Standard procedure given 3 weeks after last dose of chemotherapy</description>
    <arm_group_label>Multimodal lung sparing regimen</arm_group_label>
    <other_name>Intrapleural radiotherapy with P-32</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant mesothelioma, &lt; 20% sarcomatoid type&#xD;
&#xD;
          -  No radiographic or other imaging evidence of Stage IV (cardiac, mediastinal,&#xD;
             peritoneal, other distant) disease.&#xD;
&#xD;
          -  Ineligible for other high priority national or institutional study.&#xD;
&#xD;
          -  Age &gt;18 years [to physiologic 75 years].&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Performance status, PS 0-2 [Karnofsky Performance Status, KPS=70-100 %].&#xD;
&#xD;
          -  Prior therapy allowed (one prior systemic regimen) meeting the following parameters.&#xD;
&#xD;
          -  No prior chest radiation therapy within 6 weeks of treatment&#xD;
&#xD;
          -  No prior chemotherapy regimens within four weeks of treatment&#xD;
&#xD;
          -  Non pregnant, non-lactating. (serum HCG test will be performed in patients in whom&#xD;
             there is a possibility of pregnancy.)&#xD;
&#xD;
          -  Required initial laboratory data/clinical parameters (see also Sec. 8.0) White cell&#xD;
             count: &gt;3000/ul. Platelet count: &gt;100,000/ul. Creatinine clearance: â‰¥ 45 ml/min&#xD;
             Bilirubin: &lt; 2 x ULN SGOT or SGPT: &lt; 2 x ULN&#xD;
&#xD;
          -  Informed Consent: Each patient must be completely aware of the nature of his/her&#xD;
             disease process and must willingly give consent after being informed of the procedure&#xD;
             to be followed, the experimental nature of the therapy, alternatives, potential&#xD;
             benefits, side-effects, risks, and discomforts.&#xD;
&#xD;
          -  No other coexistent malignancy. However, curatively treated or fully controlled solid&#xD;
             tumors (other than mesothelioma) may be eligible if in the judgement of the PI, the&#xD;
             benefit of treatment outweighs the risk.&#xD;
&#xD;
          -  No serious medical or psychiatric illness preventing informed consent or intensive&#xD;
             treatment (e.g., serious infection, congestive heart failure, angina pectoris, cardiac&#xD;
             arrhythmia(s), or uncontrolled hypertension). HIV status or other severe illnesses&#xD;
             will be assessed using medical records.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If any of the inclusion criteria was not met.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert N Taub, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <results_first_submitted>October 15, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Multimodal Lung Sparing Regimen</title>
          <description>Intrapleural chemotherapy plus systemic chemotherapy:&#xD;
Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.&#xD;
Doxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.&#xD;
Cisplatin: Platinum-based antineoplastic&#xD;
Pemetrexed: Folate Analog Metabolic Inhibitor&#xD;
Radiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Multimodal Lung Sparing Regimen</title>
          <description>Intrapleural chemotherapy plus systemic chemotherapy:&#xD;
Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.&#xD;
Doxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.&#xD;
Cisplatin: Platinum-based antineoplastic&#xD;
Pemetrexed: Folate Analog Metabolic Inhibitor&#xD;
Radiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Data were not collected.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-specific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Were Able to Complete Trimodal Therapy (Combination of Surgery, Intrapleural and Systemic Chemotherapy and P-32 Radiotherapy).</title>
        <description>To determine the feasibility of multimodal lung sparing regimen. Intrapleural chemotherapy (12 weeks) will be administered within two weeks after surgery. Approximately 30 days post last dose of chemotherapy (+/- 14 days), the patient should be reassessed for resolution of any treatment-related toxicity which may have occurred during the course of study participation.</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multimodal Lung Sparing Regimen</title>
            <description>Intrapleural chemotherapy plus systemic chemotherapy:&#xD;
Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.&#xD;
Doxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.&#xD;
Cisplatin: Platinum-based antineoplastic&#xD;
Pemetrexed: Folate Analog Metabolic Inhibitor&#xD;
Radiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Were Able to Complete Trimodal Therapy (Combination of Surgery, Intrapleural and Systemic Chemotherapy and P-32 Radiotherapy).</title>
          <description>To determine the feasibility of multimodal lung sparing regimen. Intrapleural chemotherapy (12 weeks) will be administered within two weeks after surgery. Approximately 30 days post last dose of chemotherapy (+/- 14 days), the patient should be reassessed for resolution of any treatment-related toxicity which may have occurred during the course of study participation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Multimodal Lung Sparing Regimen</title>
          <description>Intrapleural chemotherapy plus systemic chemotherapy:&#xD;
Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.&#xD;
Doxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.&#xD;
Cisplatin: Platinum-based antineoplastic&#xD;
Pemetrexed: Folate Analog Metabolic Inhibitor&#xD;
Radiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to the retirement of the study physician responsible for the P-32 radiotherapy, and the need for further funding.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Taub, MD</name_or_title>
      <organization>Columbia University</organization>
      <email>rntaubipod@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

